A randomized trial comparing interferon-alpha with busulfan for newly diagnosed chronic myelogenous leukemia in chronic phase

摘要: A multicenter randomized study was conducted to compare the effect of interferon-alpha (IFN-alpha) with that busulfan in newly diagnosed patients chronic myelogenous leukemia (CML) phase. From October 1988 1991, 170 were receive either IFN-alpha or busulfan. Of 159 eligible patients, 31 (38.8%) 80 group and 43 (54.4%) 79 achieved complete hematologic remission, 38.8% 43.0% partial remission. cytogenetic response induced seven (8.8%) treated two (2.5%) busulfan, a 7.5% (6/80) 2.5% (2/79), respectively. The difference major (complete partial) between groups significant (P = .046). At median follow-up 50 months, predicted 5-year survival rate 54% 32% .0290), remaining phase 41% 29% .1165). As compared no response, any (complete, minor) after treatment significantly superior duration (IFN-alpha group; P .0017, .0010) even correction for time using landmark analysis. However, there .1065). There .3923) .6258) IFN- alpha minor). These results demonstrate produces as treatment, unexpectedly, can also eliminate Philadelphia chromosome positive clone few who showed prolonged